Stevens, Don A.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 854

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 664

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 251

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

Seymour, J. F., Cheah, C. Y., Parrondo, R., Thompson, M. C., Stevens, D. A., Lasica, M., Wang, M. L., Kumar, A., Trotman, J., Alwan, M., et al. (2023) · Blood

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 71

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Dimopoulos, M. A., Richardson, P. G., Bahlis, N. J., Grosicki, S., Cavo, M., Beksaç, M., Legieć, W., Liberati, A. M., Goldschmidt, H., Belch, A., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 48

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Schinke, C., Touzeau, C., Oriol, A., Mateos, M.-V., Stevens, D. A., Rasche, L., Qin, X., Kato, K., Ming, T., Katz, E. G., et al. (2023) · Blood

Multiple Myeloma Research and TreatmentsCancer survivorship and care

Cited by 6